Inside Precision Medicine

Clinical OMICs has transformed into Inside Precision Medicine. Inside Precision Medicine stands as the sole global media outlet dedicated to covering all aspects of precision medicine. It takes a broad view while also delving into the intricate and interconnected challenges that shape this field. With its main magazine, real-time website, a range of eNewsletters, and a variety of engaging broadcast events and multimedia content, Inside Precision Medicine serves as the essential platform for robust discussions and insights that encompass technological advancements as well as complex socio-economic and public policy matters. It also aims to provide practical solutions to the gaps that exist among various stakeholders. Inside Precision Medicine is committed to innovative thinking and actively contributing to genuine progress and change, with a focus on enhancing and streamlining the precision medicine process for the benefit of patients in need. Our main focus areas include Translational Research, Molecular Diagnostics, Informatics, and Patient Care, alongside broader coverage of Disease Indications and Payer/Regulatory topics. Our top-notch content is designed to inform, educate, and enlighten a diverse audience of researchers, pathologists, clinicians, executives, and other professionals in the field.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#545448

United States

#231634

Health/Health Conditions and Concerns

#607

Traffic sources

Monthly visitors

Articles

Liquid Biopsy Uses mRNA to Diagnose Cancer, Treatment Resistance, Tissue Damage

1 day ago | insideprecisionmedicine.com | Chris Anderson

Stanford Medicine researchers have developed a new liquid biopsy that detects cancer, resistance to cancer therapies, and tissue damage from noncancerous conditions by analyzing messenger RNA (mRNA) circulating in the bloodstream. The research, published in Nature, details this new method called RARE-seq (random priming and affinity capture of cfRNA fragments for enrichment analysis by sequencing), which took more than six years of work to make circulating RNA a viable clinical biomarker.
Psychedelic Compound’s Weeks-Long Effects Show Promise for Mental Health, Neurologic Treatments

2 days ago | insideprecisionmedicine.com | Chris Anderson

Researchers from the University of Michigan (UM) have found that a single dose of the psychedelic compound 25CN-NBOH significantly enhanced cognitive flexibility in mice for up to three weeks after administration.
Dementia Risk Drops with Blood Pressure Reduction in Hypertensives

3 days ago | insideprecisionmedicine.com | Jonathan Grinstein

New research has identified a promising link between blood pressure management and a reduced risk of dementia, according to one of the biggest and most comprehensive studies of its kind. Led by a team of scientists from the First Hospital of China Medical University in Shenyang, China, and UT Southwestern Medical Center, the trial involved 33,995 participants aged 40 or older with uncontrolled hypertension in rural China.
GLP-1 Drug Show Potential as Treatment for Bardet-Biedl Syndrome

3 days ago | insideprecisionmedicine.com | Chris Anderson

Treatment with GLP-1 receptor agonists—medications currently approved for type 2 diabetes and obesity—may offer a new therapeutic option for patients with the rare genetic disorder Bardet-Biedl Syndrome (BBS). The study, published in the Journal of Clinical Investigation, which used engineered mouse model that mirror many features of human BBS, found that GLP-1 therapies significantly improved metabolic function, reduced food intake, and helped normalize hormone levels.
Decreased Activity of Key Enzyme Accelerates Immune System Aging

6 days ago | insideprecisionmedicine.com | Chris Anderson

Researchers from the University of California, San Diego (UCSD), and UC Irvine have demonstrated that decreased activity of a lipid-synthesizing enzyme called ELOVL2 accelerates immune system aging by disrupting B cell development and altering gene expression linked to cancer. The study, published in GeroScience, found that when ELOVL2 function is impaired, it disrupts the lipid balance within cells and impairs the production of B cells, the white blood cells needed for antibody generation.
Parkinson's Cell Therapies Are Safe in Two Clinical Trials

6 days ago | insideprecisionmedicine.com | Jonathan Grinstein

Two independent teams of researchers have published clinical trial results in Nature, showcasing the safety and promise of lab-grown dopaminergic neuron progenitor cells for tackling Parkinson’s disease. By focusing on replacing the neurons lost to Parkinson’s, these therapies offer a glimpse into a future where the disease’s progression could be slowed—or even reversed.
Heart Failure Risk Predicted Using AI and Simple ECG

1 week ago | insideprecisionmedicine.com | Helen Albert

Results from an international study show that heart failure risk can be predicted using an artificial intelligence (AI) algorithm combined with a simple electrocardiogram (ECG) test that can be done in an outpatient setting.
Epilepsy Drug Resistance Linked to Genetic Variants

1 week ago | insideprecisionmedicine.com | Helen Albert

People with focal epilepsy who are resistant to available medications may be carriers of common genetic variants that impact the efficacy of these drugs. Focal epilepsy, which starts in a specific area of the brain, is the most common form of the neurological condition (61% of cases), affecting around 4 people in every 1,000. Although anti-seizure medications are available, they only work for two-thirds of people with this type of epilepsy.
Unnecessary Atherosclerosis Surgeries Could Be Avoided with Risk Tool

1 week ago | insideprecisionmedicine.com | Chris Anderson

University College London (UCL) researchers say that they have developed a new risk scoring tool that could help prevent unnecessary surgeries and stents in patients now considered at risk of stroke and heart attack. The tool, called the Carotid Artery Risk (CAR) score, stratifies patients with asymptomatic carotid atherosclerosis based on age, sex, and common cardiovascular risk factors to effectively predict future stroke and heart attack risk.
Glycomine Raises $115M for Phase IIb of Genetic Glycosylation Disorder Drug

1 week ago | insideprecisionmedicine.com | Jonathan Grinstein

At a time when securing substantial funding requires a needle through a shrinking hole, Glycomine is passed through and off to the sewing machine. The San Francisco-based company recently closed a $115 million financing round, positioning itself as a frontrunner in the fight against rare diseases, specifically, congenital disorders of glycosylation (CDGs).